Free Trial

CapsoVision (NASDAQ:CV) Rating Increased to Strong-Buy at Roth Capital

CapsoVision logo with Manufacturing background

Key Points

  • CapsoVision was upgraded to a "strong-buy" rating by Roth Capital, with a price target of $6.00, indicating a potential upside of 37.93% from its current stock price.
  • Benchmark initiated coverage on CapsoVision with a "speculative buy" rating and a price target of $5.00.
  • The stock opened at $4.35 on Monday, with a 1-year price range between $3.49 and $5.72.
  • MarketBeat previews top five stocks to own in September.

CapsoVision (NASDAQ:CV - Get Free Report) was upgraded by stock analysts at Roth Capital to a "strong-buy" rating in a note issued to investors on Monday, Marketbeat.com reports. The brokerage currently has a $6.00 target price on the stock. Roth Capital's target price indicates a potential upside of 53.45% from the stock's previous close. Roth Capital also issued estimates for CapsoVision's Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.01) EPS, FY2028 earnings at $0.35 EPS and FY2029 earnings at $0.58 EPS.

Several other brokerages also recently issued reports on CV. Benchmark started coverage on CapsoVision in a research report on Monday, July 28th. They issued a "speculative buy" rating and a $5.00 price objective for the company. Wall Street Zen raised CapsoVision to a "hold" rating in a report on Sunday, July 13th.

View Our Latest Analysis on CapsoVision

CapsoVision Stock Up 1.0%

Shares of NASDAQ CV opened at $3.91 on Monday. CapsoVision has a 52-week low of $3.49 and a 52-week high of $5.72.

About CapsoVision

(Get Free Report)

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.

See Also

Should You Invest $1,000 in CapsoVision Right Now?

Before you consider CapsoVision, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CapsoVision wasn't on the list.

While CapsoVision currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines